# Efficacy and Safety of HN2301 in Autoimmune Diseases（AIDs）

> **NCT06801119** · PHASE1 · RECRUITING · sponsor: **Shenzhen MagicRNA Biotechnology Co., Ltd** · enrollment: 30 (estimated)

## Conditions studied

- Systemic Lupus Erythematosus
- Scleroderma
- Rheumatoid Arthritis

## Interventions

- **DRUG:** HN2301 injection

## Key facts

- **NCT ID:** NCT06801119
- **Lead sponsor:** Shenzhen MagicRNA Biotechnology Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-16
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-06-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-04-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06801119

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06801119, "Efficacy and Safety of HN2301 in Autoimmune Diseases（AIDs）". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06801119. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*